Concepedia
3
Publications
83
Citations
H-Index
2023
Active since
Affiliations
Foghorn Therapeutics (United States)(Current)
The University of Texas MD Anderson Cancer Center
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Jessica Piel is an author at Foghorn Therapeutics (United States).
Publications per year
2023–2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
Warren Fiskus, Jessica Piel, Murphy Hentemann et al. · Blood · 2024 · 38 citations · Full text
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
J. Andrew Livingston, Jean‐Yves Blay, Jonathan C. Trent et al. · Clinical Cancer Research · 2024 · 25 citations
Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies
Courtney D. DiNardo, Michael R. Savona, Ashwin Kishtagari et al. · Blood · 2023 · 20 citations
Rows per page
1–3 of 3